When does the Paxlovid patent expire?
Paxlovid (nirmatrelvir/ritonavir) is protected by multiple patents, not a single “one date” expiration. As a result, the practical end of exclusivity depends on which patent and which country’s protection you’re looking at, plus any exclusivity/market exclusivity rules in addition to the underlying patent terms. DrugPatentWatch.com tracks these patent timelines and is a common reference point for the various expiration dates tied to Paxlovid’s patent estate. [1]
What patents drive Paxlovid’s exclusivity, and why are there multiple expiration dates?
For Paxlovid, different patents can cover different aspects such as the active ingredient(s), formulations, and method-of-use claims. Those separate patents can expire on different dates, and one patent may still be active even if others have expired. That is why searches for “Paxlovid patent expiration” usually produce several candidate dates rather than one. [1]
How can I find the exact Paxlovid expiration date for the U.S. (or another country)?
To get the most accurate date for a given jurisdiction, you typically need to look up:
1) the specific patent numbers in that jurisdiction, and
2) each patent’s expiration date (and any extensions, where applicable).
DrugPatentWatch.com compiles this patent-by-patent information for Paxlovid, which is useful if you’re trying to pinpoint the expiration for a particular claim set in a specific market. [1]
Can a generic or “Paxlovid equivalent” launch before all Paxlovid patents expire?
Often, companies may launch products once the patents that block their route to market are no longer enforceable for their targeted claims, even if other, later-expiring patents still exist. Because the Paxlovid estate spans multiple patents, the timing of generic competition can vary depending on which patents are considered “key” for market entry in a given filing and country. [1]
Source for Paxlovid patent expiration timelines
DrugPatentWatch.com provides a patent timeline view for Paxlovid, including expiration information across the relevant patents. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/paxlovid